PCM
CRSP icon

Prelude Capital Management’s CRISPR Therapeutics CRSP Stock Holding History

Prelude Capital Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-3,500
Closed -$219K – 1350
2023
Q4 		$219K Buy
+3,500
New +$193K 0.01% 905
2022
Q1 		– Sell
-4,200
Closed -$318K – 1895
2021
Q4 		$318K Buy
+4,200
New +$367K 0.01% 1284

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Prelude Capital Management's CRSP Position: Q1 2025 in Review

Prelude Capital Management sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 15,000 shares — an estimated $590K sold.

Prelude Capital Management first reported a position in CRSP in Q4 2017 and held it in 9 quarters. The position peaked at $590K in Q4 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • Prelude Capital Management reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Prelude Capital Management sold 15,000 CRISPR Therapeutics shares in Q1 2025, an estimated $590K.
  • Prelude Capital Management first reported a position in CRISPR Therapeutics in Q4 2017 and held it in 9 quarters.
  • Prelude Capital Management's CRISPR Therapeutics position peaked at $590K in Q4 2024.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on Prelude Capital Management's 13F filing for Q1 2025, filed 15 May 2025.